original contributions nature publishing group Several studies provide mounting evidence that even mild kidney dysfunction is accompanied by accelerated cardiovascular (CV) damage. 1 Microalbuminuria (MA), which constitutes both marker of target organ damage in hypertension (HT) at kidney level and hallmark of incipient nephropathy in diabetics, 2 is also recognized as a potent independent prognosticator of atherosclerotic CV disease not only in diabetic, 3 but also in nondiabetic patients 4 including hypertensives and the general population. 5-7 Focusing on HT, the presence of MA conveys an increased risk for atherogenic vascular damage 6, 7 and, according to current guidelines for the management of HT, its evaluation is useful for the risk stratification in this setting. 8 In cross-sectional studies, the correlation of MA with other surrogate markers of adverse CV outcome, like left ventricular mass index (LVMI) and aortic stiffness, has already been demonstrated. 9, 10 MA is not only associated with adverse CV outcome, but there are also some data showing that normalization of MA might reflect a trend for CV events' reduction 6 and that treatment with albuminuria-lowering properties is associated with beneficial clinical outcome. 11 According to the Losartan Intervention For Endpoint reduction study, reduction in albuminuria translates into reduction of CV events in hypertensive subjects, independently of both antihypertensive treatment used and blood pressure (BP) levels. 12 Although the regression of albuminuria does not represent a primary therapeutic goal, the recognition of precipitating factors associated with newonset MA would be of great clinical importance.
Several studies provide mounting evidence that even mild kidney dysfunction is accompanied by accelerated cardiovascular (CV) damage. 1 Microalbuminuria (MA), which constitutes both marker of target organ damage in hypertension (HT) at kidney level and hallmark of incipient nephropathy in diabetics, 2 is also recognized as a potent independent prognosticator of atherosclerotic CV disease not only in diabetic, 3 but also in nondiabetic patients 4 including hypertensives and the general population. [5] [6] [7] Focusing on HT, the presence of MA conveys an increased risk for atherogenic vascular damage 6, 7 and, according to current guidelines for the management of HT, its evaluation is useful for the risk stratification in this setting. 8 In cross-sectional studies, the correlation of MA with other surrogate markers of adverse CV outcome, like left ventricular mass index (LVMI) and aortic stiffness, has already been demonstrated. 9, 10 MA is not only associated with adverse CV outcome, but there are also some data showing that normalization of MA might reflect a trend for CV events' reduction 6 and that treatment with albuminuria-lowering properties is associated with beneficial clinical outcome. 11 According to the Losartan Intervention For Endpoint reduction study, reduction in albuminuria translates into reduction of CV events in hypertensive subjects, independently of both antihypertensive treatment used and blood pressure (BP) levels. 12 Although the regression of albuminuria does not represent a primary therapeutic goal, the recognition of precipitating factors associated with newonset MA would be of great clinical importance.
Toward this end, in this study, we attempted to investigate the main determinants of MA development in newly diagnosed hypertensive subjects, undergoing implementation of "de novo" antihypertensive treatment. We hypothesized that LVMI and its changes may predict future new-onset MA.
Methods
Study design. A longitudinal prospective design was chosen to address the main purpose of the study. Participants were original contributions LV Mass Index and New-Onset Microalbuminuria progressively enrolled at the outpatient hypertensive clinic of our institution between January 2003 and January 2008. From January 2008 to January 2009 last visit measures were registered. At baseline, a careful medical history including the assessment of lifestyle attitudes was obtained for all participants; participants also underwent clinical, echocardiographic, and MA examinations. Office BP evaluation and ambulatory BP monitoring were scheduled at both baseline and last followup visit. Antihypertensive therapy was prescribed in line with the current guidelines 8 and included lifestyle changes and/ or drug treatment. Modifications in antihypertensive therapy were implemented to achieve BP control (i.e., office systolic and diastolic BP <140 mm Hg and <90 mm Hg, respectively) in the period between baseline and last follow-up visit. In the same period, routine biochemical blood examinations were prescribed to assess metabolic and kidney function profile. At last follow-up visit, echocardiographic and MA examinations were also assessed (Figure 1) . The study protocol complies with the Declaration of Helsinki, was approved by our local institutional Ethics Committee, and all participants gave written informed consent.
Study population. A total of 660 white subjects, aged >18 and <85 years with untreated newly diagnosed (<2 years) office HT, who were referred to our outpatient HT unit, were recruited. Exclusion criteria included stage III HT or secondary HT (n = 60, 9.1%), white-coat HT (office systolic blood pressure (SBP) >140 mm Hg or diastolic blood pressure (DBP) >90 mm Hg and daytime SBP <135 mm Hg and daytime DBP <85 mm Hg) (n = 73, 11%), history of coronary artery disease, cerebrovascular disease or congestive heart failure (n = 51, 7.7%), atrial fibrillation (n = 55, 8.3%), diabetes mellitus (n = 83, 13%), impaired glucose tolerance (n = 31, 5%), baseline MA (albumin to creatinine ratio (ACR) ≥20 and <300 mg/g in men or ≥30 and <300 mg/g in women as an average of two nonconsecutive morning spot urine samples (n = 73, 11%), overt proteinuria (≥300 mg/g) or renal dysfunction (creatinine clearance (CrCl) according to the Cockroft-Gault formula <60 ml/min) (n = 20, 3%), presence of neoplastic or any other concurrent systemic disease (n = 7, 1%). After the implementation of the exclusion criteria 207 subjects with sustained essential HT stage I-II, confirmed by ambulatory BP monitoring (daytime systolic/ diastolic BP ≥135/85 mm Hg) 13 were eligible for the analysis (Figure 1) .
Baseline evaluation. Body size parameters were registered and patients underwent the examinations recommended by the current guidelines for the management of HT. Office and ambulatory BP measurements, in tandem with MA assessment and complete echocardiographic study were also performed. For baseline BP, we considered the average of BP measurements recorded before the institution of any antihypertensive therapy.
Follow-up procedures. After enrollment, all patients were instructed to pursue standard lifestyle measures and were also treated with pharmacological antihypertensive treatment if lifestyle modification proved ineffective. In those treated initially only by lifestyle measures an early visit at 1 or 2 months (depending on relative individual CV risk, according to the guidelines for the management of HT) was performed. The overall therapy was complemented by supplementary vasoactive drugs (statins, antiplatelet agents), where indicated. All the subjects were periodically referred to the outpatient hypertensive unit of our institution, at least two times annually, for evaluation of BP control and each participant had at least 1 year of follow-up. For last visit BP, we considered the average of the measurements recorded during a 3-month period around the date of the last visit. Data regarding the last visit included: office BP measurements, ambulatory BP monitoring, MA determination, LVMI evaluation, metabolic profile and CrCl evaluation, and registration of implemented pharmacotherapy. Main outcome variable was new-onset MA. We considered sufficient BP control levels of office BP to be <140/90 mm Hg in ≥75% of total number of visits during the follow-up period. LVMI reduction was defined as the decline of LVMI at the end-follow-up of ≥15% with respect to the baseline value, according to the LIFE study results. 14 
Measurements
Office and ambulatory BP. Office BP was measured with the patient in the sitting position after a 5-min rest as the average of three consecutive measurements according to the recent guidelines. 13 Ambulatory BP was recorded over a working day (Monday through Friday) using the automatic Spacelabs units 90207 (Redmond, WA) that was set to obtain automatic heart rate and BP readings at 15-min intervals during the daytime and at 30-min intervals during the nighttime. In accordance with current practice, daytime and nighttime were defined using short fixed-clock time intervals, which ranged from 1000 to 2000 h and from 0000 to 0600 h, respectively, while automatic editing was used. Twenty-four hour systolic and diastolic BP values were the mean of the overall 24-h recordings after artifact editing.
LVMI assessment. The echocardiographic studies were performed by an experienced senior echocardiographer who was blind to the clinical status of the examined subject, according to the recommendations of the American Society of Echocardiography. 15 Intraobserver variability of the operator for left ventricular (LV) mass in the setting of newly diagnosed untreated hypertensive patients was 4.5 ± 10.4 g (coefficient of intrareader variation: 9.5%). LV mass was calculated using the method of Devereux et al. 14 and normalized for body surface area to obtain LVMI. In addition, LV mass was indexed for height raised to the 2.7 power (g/m 2.7 ) to provide a more stringent allowance for body size. LV hypertrophy (LVH) was defined as LV mass indexed for body surface area ≥116 g/m 2 in men and ≥96 g/m 2 in women or as LV mass indexed for height 2.7 ≥49 g/m 2.7 in men and ≥45 g/m 2.7 in women. 16 Biochemical assessment. Venous blood samples were obtained from each participant in the morning (from 0700 to 0800) after an overnight fasting for the determination of plasma glucose, serum creatinine, and lipid profile (i.e., total cholesterol, triglycerides, low and high-lipoprotein cholesterol). Plasma glucose, total cholesterol, and high-density lipoprotein cholesterol were determined by spectrophotometric methods. Low-density lipoprotein cholesterol and CrCl were calculated by the Friedewald and Cockcroft-Gault formulas, respectively. MA evaluation was made by using a quantitative assay (DCA 2000; Bayer Diagnostics Europe, Dublin, Ireland) with a coefficient of variation 2.8% as the average of two overnight spot urine samples with a mean elapsing time of 2 weeks. If one collection demonstrated abnormal levels of MA or proteinuria and the other did not, a further collection was made with a mean elapsing time of almost 2 weeks to avoid misclassification of patients.
Statistical analysis. SPSS statistical package, release 16.0 (SPSS, Chicago, IL) was used for all statistical analyses. The normality of the distribution of the continuous variables was tested by using the Shapiro-Wilk statistic, and all variables had normal distribution except for ACR, which was logarithmically (log 10 ) transformed before statistical testing, because of the skewed distribution. Categorical variables are presented as absolute frequencies and percentages, whereas the continuous variables as means and s.d. The difference (Δ) between baseline and last value of each variable was defined as baseline value minus last visit value. We performed paired-samples t-test to compare the mean values of the variables for the study population at baseline and at last follow-up visit. Cox proportional hazard models were used to assess the effect, presented as hazard ratios and 95% confidence intervals, of different determinants on the development of MA. Univariate models were used to assess the significant predictors of the outcome in those patients developing MA, while multivariate analyses included the significant univariate determinants (i.e., baseline LVMI, LVMI reduction, and BP control) as well as age, sex, baseline body mass index, baseline CrCl, baseline original contributions LV Mass Index and New-Onset Microalbuminuria daytime SBP and DBP implemented by forced entry into the model. All tests were considered to be significant at the level of P value <0.05.
results
A total of 207 hypertensive, nondiabetic, normoalbuminuric subjects, (mean age 50.8 ± 10.1 years, 132 males, office BP = 148/96 mm Hg) were prospectively studied for a mean followup period of 3.3 ± 1.3 years. The mean number of visits for the total population during the follow-up period was 4.2 ± 3.4. Of the total population 5.8% (n = 12) developed MA, with a rate of 1.8 per 100 patient-years. Among patients who developed MA, log 10 ACR increased from 0.94 ± 0.33 to 1.57 ± 0.27 mg/g in the last visit (P <0.01).
The clinical characteristics of the sample regarding both baseline and last visit are presented in Table 1 . A percentage of 64.3% (n = 133) of patients achieved sufficient BP control during the follow-up period. All patients with sufficient office BP control during follow-up had ambulatory BP levels within the normal range in the last visit. However, the proportion of patients with BP control out-of-goal during follow-up (i.e., n = 74) had daytime SBP and daytime DBP within the goal in 8% (i.e., white-coat effect) of the cases. A decrease between baseline and last visit was observed in the following hemodynamic parameters: Δ24-h SBP = 13 ± 12 mm Hg, Δ24-h DBP = 9 ± 8 mm Hg, ΔOffice SBP = 16 ± 14 mm Hg, ΔOffice DBP = 11 ± 10 mm Hg. (P < 0.01 for all). Body mass index was decreased by 1.0 ± 5.2 kg/m 2 and current smokers by 10.6%, while there was an increase in waist circumference by 1.1 ± 6.7 cm (P < 0.05 for all). No difference was observed in glucose, CrCl and creatinine levels, while low-density lipoprotein cholesterol levels were diminished by 12.6 ± 37.5 mg/dl, P< 0.01. None of the patients developed diabetes mellitus during the follow-up period.
There was an increasing trend for log 10 ACR in the total population from 0.85 ± 0.31 to 0.89 ± 0.29 mg/g (P > 0.05). A reduction in LVMI was noticed (ΔLVMI = 6.84 ± 21.5 g/m 2 , P < 0.01). Eighty-seven subjects (42%) already demonstrated LVH at baseline. At last follow-up visit, two patients (1%) had both LVH and MA. In Table 2 , we present the implemented pharmacotherapy during the follow-up period.
Univariate Cox regression analysis revealed that the significant univariate determinants of new-onset MA were baseline LVMI, LVMI reduction, and BP control ( Table 3) , whereas the results of multivariate analysis are presented in Table 4 . Accordingly, increase of LVMI by 1 s.d. (23.3 g/m 2 ) conferred a 15% increased risk for new-onset MA, LVMI reduction decreased the risk by 99.4%, and BP control by 97.1% in the same direction.
In a step further, we repeated the multivariate Cox regression analysis by replacing LVMI and LVMI reduction with LV mass/height 2.7 and with LV mass/height 2.7 reduction, respectively. Increase of LV mass/height 2.7 by 1 s.d. (11.4 g/m 2.7 ) conferred 20% increased risk for new-onset MA, LV mass/ height 2.7 reduction diminished the risk by 97.6%, and BP control decreased the risk by 93.7% (Table 5 ).
discussion
One of the novel findings of this study is that baseline LVMI was a significant predictor of new-onset MA over a period of >3 years. In addition, the reduction of LVMI proved to be a significant negative predictor of MA development, as it reflected original contributions
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an almost halving risk for MA incidence. Achievement of BP levels within the goal during follow-up period represented a further significant predictor of retaining albuminuria within normal levels. LVMI is considered as a strong predictor of unfavorable CV events in hypertensive populations. 17, 18 Losartan intervention for endpoint reduction and other prospective studies confirmed that the regression of LVH conveys beneficial effects on the long-term prognosis, independently of BP control. [19] [20] [21] In an earlier retrospective longitudinal study including high-CV risk veterans followed up for 15 years, baseline LVMI was an independent predictor of progressive kidney function decline by means of accelerated glomerular filtration rate reduction. 22 In this study, baseline LVMI qualified as an accelerator of kidney damage by means of MA. However, the underlying mechanisms justifying the predictive impact of LVMI on incident MA are rather unclear. Common pathophysiological denominators modulating the latter relationship include the increased haemodynamic load, sympathetic and renin-angiotensin system overactivity, 23 increased subclinical inflammatory reaction, and production of reactive oxygen species, [24] [25] [26] that in combination or separately induce fibrotic phenomena at the heart and the kidney. 27 In another view, LVH-associated diastolic dysfunction enhances central venous congestion further impairing kidney hemodynamics and promoting MA. To what extent the increased values of LVMI participate in the aforementioned pathophysiological processes which have been postulated to precede and predict the onset of MA 28 warrants further investigation.
Our study shows that the reduction of LVMI reduced the incidence of MA overtime. Therefore, the already established predictive value of LVMI reduction on cardioprotection is extended to decreased risk of MA development. Although the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) 29 showed that in patients with increased CV risk, the reduction of MA was LVMI reduction was defined as the decline of LVMI at end-follow-up of 15% with respect to the baseline value; BP control was defined as levels of office BP ≤140/90 mm Hg in 75% of total number of visits during the follow-up period. ACR, albumin to creatinine ratio; BP blood pressure; CCBs, calcium channel blockers; CI, confidence interval; CrCl, creatinine clearance; DBP, diastolic blood pressure; HR, hazard ratio; LDL, low-density lipoprotein; LVMI, left ventricular mass index; MA, microalbuminuria; RAS, renin-angiotensin system; SBP, systolic blood pressure; TD, treatment duration; Δ, difference.
original contributions LV Mass Index and New-Onset Microalbuminuria not accompanied by nephroprotection; MA remains a marker of early renal dysfunction in uncomplicated HT; thus, LVMI levels and the reduction of LVMI may have a role in the risk stratification for renal outcomes in hypertensive subjects. In addition, sufficient BP control during follow-up was a main negative determinant of new-onset MA. Treatment with specific antihypertensive drug regimens did not prove to be significant determinant of developing MA. However, our study was not powered to detect the differential impact of specific drug treatment on the incident MA, whereas BP reduction within the goal qualified as essential contributor of sustained normoalbuminuria over a period of >3 years.
Another issue that should be pointed out is the absence of CrCl decline in our population during the follow-up period. On the basis of cross-sectional and few longitudinal studies, the average rate of normal CrCl decline is about 0.8-1.0 ml/ min/year after the age of 30. 30 However, the substantial proportion of patients with sufficient BP control, and under treatment with renin-angiotensin system inhibitors in tandem with low albuminuria progression in the total population, might have eliminated some of the modifiable parameters modulating CrCl decline. Moreover, another confounding factor is the lack of annual testing of CrCl for a long period, which limits the real rate of decline 30, 31 and finally the fact that our study was not powered to evaluate prospective changes in CrCl.
Certain limitations should be acknowledged. First, this is not a randomized trial and as such is subject to shortcomings. Second, it included only white subjects with new diagnosis of HT and the data may not be applicable to other populations including the more enhanced CV disease burden. Third, the results of multivariate analyses were not adjusted for antihypertensive treatment, the event per variable ratio was relatively small and finally the study was not designed to detect differences in the array of drug regimens used. Lastly, potential confounding effect of hygienic treatment including dietetic measures and physical activity during the follow-up could not be ruled out by the design of the current study. However, strengths of the study are the dual nonconsecutive measurement of albuminuria, the implementation of ambulatory BP monitoring at both baseline and follow-up, and the close visitto-visit evaluation of the long-term BP variability as assessed by interim checking of BP control.
In conclusion, LVMI and its reduction qualified as predictors of new-onset MA in newly diagnosed hypertensive patients without clinically evident organ damage, beyond BP control. 
